Transcript Slide 0 - Thomas Jefferson University

Partnering for Growth
Thomas Jefferson University, June 7th, 2013
Chris Yochim, Director, External Relations
Strategic Partnering and Business Development
Partnering for Growth
Agenda
• Our strategic priorities and
platforms for growth
• Partnering strategy and
capabilities
• Academic Collaborations to
drive scientific leadership
2
Driving strategic priorities
Focus on 3 distinct core disease areas
Prioritise and accelerate our pipeline
Achieve scientific
leadership
Strengthen our capabilities in translational
science and personalised medicine
Transform our innovation and culture model
3
We will focus on distinctive science in our
core therapy areas
CardioMetabolism
Oncology
Respiratory/
inflammation
Infection &
Vaccines
Core TAs
Biologics
4
Small
Molecules
Neuroscience
Opportunity-Driven
Immuno-therapies
Protein
engineering
Build biologics/specialty care potential to drive
sustainable longer term growth
Return
to growth
Development Pipeline Today
~50%
Biologics
~50%
Small
Molecules
Development (Phase I-III) pipeline today
has grown to ~50% biologics
BLA = Biologics License Application
5
•
On track for sustainable delivery of
1 BLA/year from 2016
•
Convert strong biologics pipeline
into future launches
•
Create a balanced primary and
specialty care product portfolio
2
AZ Emerging Markets – A platform for success
6th
Russia
fastest growing MNC
pharma player
across Emerging
Markets
~$300 Million
Turkey
~$250 Million
China
~$6bn
sales in Emerging
Markets
~$1.5 Billion
S. Korea
Mexico
~$240 Million
~$240 Million
Brazil
~$500 Million
Saudi Arabia
~$170 Million
Source: Internal 2012 Ex Factory Sales / IMS
6
Partnering for Growth
Agenda
• Our strategic priorities and
platforms for growth
• Partnering strategy and
capabilities
• Academic Collaborations to
drive scientific leadership
7
Working in collaboration is an ongoing part of
our new strategy
AstraZeneca partnering strategy is focused on
supplementing and complementing our core therapy
areas and scientific capabilities
Approximately 40% of our pipeline is sourced
through external partnerships
Increased focus on early stage research deals and
academic alliances in 2013
Pursue in-licensing and bolt-on acquisitions that
strengthen the core TA portfolios
Seek 1-2 additional global peer-to-peer partnerships
beyond BMS and Amgen alliances
8
Building direct early access to our R&D
Cardiovascular/
Gastrointestinal
Oncology
New
Opportunities
Respiratory and
Inflammation
Infection
Discovery and Early Development
Innovative
Medicines Units
Small Molecules
Internal
and external
opportunities
Innovative
Medicines Units
Biologics
Scouting
CNS
and Pain
Science and
Technology
Emerging
Markets and
Asia R&D
Late-stage
Development
Global
Medicines
Development
Diligence
Transaction
R&D Enabling
functions Alliance Mgmt
Cross functional transaction team
9
Personalised
Healthcare and
Biomarkers
Market
As a Commercial partner
we bring....
10

Truly global commercial operations footprint with
both primary and specialty care focus

A large and growing presence in emerging markets
including China, Brazil, Russia

Sales, marketing and medical excellence to tailor
brands and drive performance in 100 countries

Innovative sales and marketing channels to better serve
the needs of today’s customers

Life-cycle management expertise to help extend the
value of the products we market
As a Development partner
we bring...
11

A global R&D footprint with local insights
and capabilities

75% of our portfolio applies a personalised
healthcare approach

90% of pipeline addresses payer evidence
to support reimbursement

87% of projects apply new methods of
clinical design and interpretation

World-class regulatory, manufacturing
and protein engineering capabilities
Partnering for Growth
Agenda
• Our strategic priorities and
platforms for growth
• Partnering strategy and
capabilities
• Academic Collaborations to
drive scientific leadership
12
Academic Alliance: History of strategic collaboration
• Key Strategic Alliances (Since Jan 2011)
• Collaborative Research (201)
• Consortiums & Foundations (41)
–
–
–
–
–
Dundee
Biomarker/Safety
Regional Economic Development
Medicines for Malaria
TB Consortium
• MTA’s 300+
13
Creative alliances to drive early scientific discovery
projects
•
A5 alliance, to study a major risk factor for Alzheimer's disease,
the apolipoprotein E4 genotype (ApoE)
– Alzheimer's Disease Research Institute at Weill Cornell, Washington
University in St Louis, The Feinstein Institute for Medical Research and the
University of British Columbia.
•
7 Way-Consortium: Critical Path to TB Drug Regimens
– AstraZeneca, Bayer, Sanofi and Tibotec have signed on with TB Alliance
and the World Health Organization to share information about the TB
compounds in their pipelines to quickly identify and collaborate to develop
the most promising TB drug regimens
•
AZ & GSK forge alliance with Univ. Manchester Collaborative
Centre for Inflammation
– Unique Pre-Competitive collaboration to establish a world-leading
translational centre for inflammatory diseases. Scientists will be recruited for
new positions to direct the research in line with strategic priorities set jointly
by GSK, AstraZeneca and The University of Manchester, with the ultimate
goal of translating findings into new and improved treatments.
•
Broad Institute
– The Broad Institute's 100,000 compound library will be tapped for weapons
against drug resistant strains of bacteria. targeted towards the discovery of
new antibiotics and other treatments for infectious diseases.
14
Fostering Alliances for Clinical Development
•
Fostering helps us to broaden our drug development activity by
working with experienced clinical development institutions which
can take the lead on early-stage development of AstraZeneca
compounds. When the compounds reach the proof-of-concept
stage, we can opt in and continue development with a milestone
payment, or we can opt out and receive a royalty later on when the
compound is approved and commercialized
– Singapore National University and the National Cancer Centre
development of AstraZeneca compounds for hepato-cellular carcinoma
which have already undergone clinical testing in western locations.
Applying their experience to conduct clinical trials in wider patient
populations, broadening our drug development capabilities in Asia.
– Cancer Research UK and Cancer Research Technology - the charity's
development and commercialisation arm. AstraZeneca’s compound, AZD3965 – a first-of-its-kind experimental drug to potentially treat a range of
cancers- into clinical development. Working with CRT will enable a
compound with a very exciting mechanism to be evaluated in patients using
Cancer Research UK’s extensive clinical network.
15
Partnering areas of interest
Cardiovascular & Gastrointestinal
• Our research focuses on small molecule and biologics for diabetes and
diabetic complications, obesity, atherosclerosis, haemostasis,
gastrointestinal, abdominal aortic aneurysm, bleeding disorders as well
as re-profiling compounds, innovative drug-delivery systems and
regenerative medicine.
Oncology
• Our small and large molecule research focuses on cancer of the
breast, prostate, gastrointestinal tract, lung, as well as haematological
malignancies, “niche” cancers, novel technologies and biomarkers.
Respiratory & Inflammation
• We are particularly interested in asthma, chronic obstructive pulmonary
disease, rheumatoid arthritis, systemic lupus erythematosus and novel
inhalation approaches.
16
Partnering areas of interest
Infection
• Our partnership interests also include: viral infections such as respiratory
viruses (e.g flu, RSV), HCV, HBV and herpes family viruses, as well as
systemic fungal infections, and diagnostics. Novel vaccines to address
bacterial and viral infections with limited current treatment options are also
of interest.
Neuroscience
• We are interested in small and large molecule research to discover and
develop new treatments in neurology, psychiatry and pain.
Personalised Healthcare & Biomarkers
• We are looking for additional biomarker capabilities that can deliver clinically
meaningful segmentation of therapeutic response, including methodology
for patient selection, disease identification, and pharmacological
assessment.
Science & Technology
• Key areas of interest include predictive safety and predictive efficacy
platforms, target validation tools and technologies, novel HTS/lead
generation approaches, novel chemical libraries with evidence of biological
relevance, stem cell biology and, novel technologies for antibodies and
vaccines.
17
Personalised Healthcare – an open approach to
collaboration
• Partnership and collaboration at
the core of PHC strategy
– No single partner can address all of
our PHC needs
– Series of partnerships will help us to
achieve our aims
• Strategic alliances with key
academic centres and
independent diagnostic
developers
• Early engagement with partners
enables us to share needs and
match up partner products
18
Diligence Process: Five Dimensions for success
19
Right target
• Strong link between target and disease
• Differentiating efficacy
• Available and predictive biomarkers
Right tissue/
Right exposure
• Adequate bioavailability and tissue exposure
• Human PK / PD prediction, PD biomarkers
• Drug-drug interaction
Right safety
• Clear assessment of safety risks
• Clear understanding of risk-benefit
• Availability of predictive biomarkers
Right patients
• Scientific evidence in lead indication
• Risk / benefit stratification of patient population
• PHC strategy including diagnostic / biomarkers
Right commercial
•
•
•
•
Differentiated value proposition vs. future standard of care
Invest to win / priority areas – DTPP / CDTP
Market access / payer / provider focus
Personalised healthcare strategy including diagnostic / biomarkers
Why Partner with AstraZeneca?
Exclusive focus on innovative
pharmaceutical medicines
Focused commitment to early and
late-stage partnering
Innovative commercial channels,
underpinned by global reach
Access to early payer and regulatory
involvement to secure reimbursement
and market access
Exceptional commercial and R&D
presence in emerging markets
and Asia
Expertise in biologics and small
molecule discovery, development
and manufacturing
Rapid evaluation and insightful
feedback to partners
Alliance management continuity
throughout the deal life cycle
Desire to create partnerships
that achieve mutual goals
20
20
For more information about partnering
with AstraZeneca, visit
astrazeneca.com/partnering
[email protected]
21